Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2026 Feb 1;15(1):15.
doi: 10.21037/hbsn-2025-587. Epub 2026 Jan 19.

Neoadjuvant therapy for left-sided resectable pancreatic ductal adenocarcinoma: evidence-based shift or premature extrapolation?

Faik G Uzunoglu  1 , Christoph Springfeld  2 , Teresa Peccerella  3 , Thomas Hank  3 , Martin Loos  3 , Christoph W Michalski  3 , Thilo Hackert  1 , John P Neoptolemos  3
Affiliations
Editorial

Neoadjuvant therapy for left-sided resectable pancreatic ductal adenocarcinoma: evidence-based shift or premature extrapolation?

Faik G Uzunoglu et al. Hepatobiliary Surg Nutr. .
No abstract available

Keywords: Neoadjuvant; adjuvant; body and tail pancreatic cancers; left-sided pancreatectomy; resectable.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-2025-587/coif). C.S. declares advisory board membership for Astra Zeneca, Bayer, BMS, Roche, Incyte, MSD, Revolution Medicines, Servier and Taiho; travel support from Servia; honoraria for a lecture from Roche. J.P.N. declares that he has received grants from the Heidelberger Stiftung Chirurgie, Dietmar Hopp Stiftung GmbH, Bundesministerium für Bildung und Forschung and the Stiftung Deutsche Krebshilfe; consulting fees from Clarivate Analytics (UK) Limited, and ONO Pharmaceuticals; advisory board membership for BioNTech (BNT32); and the patent 52378-704.601 PCT 23 May 2025, Combination of Irinotecan and AP-001 for treating cancer. The other authors have no conflicts of interest to declare.

Comment on

  • The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study.
    Rangelova E, Stoop TF, van Ramshorst TME, Ali M, van Bodegraven EA, Javed AA, Hashimoto D, Steyerberg E, Banerjee A, Jain A, Sauvanet A, Serrablo A, Giani A, Giardino A, Zerbi A, Arshad A, Wijma AG, Coratti A, Zironda A, Socratous A, Rojas A, Halimi A, Ejaz A, Oba A, Patel BY, Björnsson B, Reames BN, Tingstedt B, Goh BKP, Payá-Llorente C, Del Pozo CD, González-Abós C, Medin C, van Eijck CHJ, de Ponthaud C, Takishita C, Schwabl C, Månsson C, Ricci C, Thiels CA, Douchi D, Hughes DL, Kilburn D, Flanking D, Kleive D, Silva DS, Edil BH, Pando E, Moltzer E, Kauffman EF, Warren E, Bozkurt E, Sparrelid E, Thoma E, Verkolf E, Ausania F, Giannone F, Hüttner FJ, Burdio F, Souche FR, Berrevoet F, Daams F, Motoi F, Saliba G, Kazemier G, Roeyen G, Nappo G, Butturini G, Ferrari G, Kito Fusai G, Honda G, Sergeant G, Karteszi H, Takami H, Suto H, Matsumoto I, Mora-Oliver I, Frigerio I, Fabre JM, Chen J, Sham JG, Davide J, Urdzik J, de Martino J, Nielsen K, Okano K, Kamei K, Okada K, Tanaka K, Labori KJ, Goodsell KE, Alberici L, Webber L, Kirkov L, de Franco L, Miyashita M, Maglione M, Gramellini M, Ramera M, Amaral MJ, Ramaekers M, Truty MJ, van Dam MA, Stommel MWJ, Petrikowski M, Imamura M, Hayas… See abstract for full author list ➔ Rangelova E, et al. Ann Oncol. 2025 May;36(5):529-542. doi: 10.1016/j.annonc.2024.12.015. Epub 2025 Jan 13. Ann Oncol. 2025. PMID: 39814200

References

    1. Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001;358:1576-85. 10.1016/s0140-6736(01)06651-x - DOI - PubMed
    1. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200-10. 10.1056/NEJMoa032295 - DOI - PubMed
    1. Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010;304:1073-81. 10.1001/jama.2010.1275 - DOI - PubMed
    1. Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 2017;389:1011-24. 10.1016/S0140-6736(16)32409-6 - DOI - PubMed
    1. Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med 2018;379:2395-406. 10.1056/NEJMoa1809775 - DOI - PubMed

LinkOut - more resources